Foster City, Calif., September 20, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is issuing a voluntary recall of one lot of Veklury® (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer complaint and confirmed the presence of a glass particle in
Similar Posts
Section 804 Importation Program Policies and Authorizations
FDA has issued policies and taken actions to implement section 804 of the Federal Food, Drug and Cosmetic Act, which allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.eCTD Submission Standards for eCTD v3.2.2 and Regional M1
eCTD Submission StandardsZydus Lifesciences Limited – 08/13/2025
Zydus Lifesciences Limited – 08/13/2025. Country: India. Record Type: 483POSTPONED – 17th Annual Sentinel Initiative Public Workshop – 11/06/2025
The U.S. Food and Drug Administration, under a cooperative agreement with the Duke-Margolis Institute for Health Policy, is hosting the 16th Annual Sentinel Initiative Public Workshop on November 6, 2025FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related eventsEmergency Use Authorizations for Drugs and Non-Vaccine Biological Products
Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products